Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience

BACKGROUND: Treatment with radium-223 has been shown to increase survival and to delay skeletal events related to bone metastases of patients with metastatic Castration Resistant Prostate Cancer (mCRPC). This treatment has also proved to be well tolerated, and hematological toxicity, in particular a...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Renato P., Bordonaro, Sebastiano, Cappuccio, Francesco, Tripoli, Vincenzo, Murabito, Alessandra, Licari, Maria, Valerio, Maria R., Tralongo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424691/
https://www.ncbi.nlm.nih.gov/pubmed/30937295
http://dx.doi.org/10.1016/j.prnil.2018.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424691/
https://www.ncbi.nlm.nih.gov/pubmed/30937295
http://dx.doi.org/10.1016/j.prnil.2018.08.001

Ejemplares similares